CRA was commissioned by AstraZeneca to investigate the economic and societal burden associated with Acute Coronary Syndrome (ACS) in Canada. This short paper represents a summary of the full report.
GLP-1 access is shifting – Are stakeholders ready?
CRA’s Becky Davis examines how these dramatic price reductions, combined with Direct-to-Patient distribution models, may be accelerating employer migration...
